key: cord-0801799-yvapzwm2
authors: Darling, Tamarand L.; Ying, Baoling; Whitener, Bradley; VanBlargan, Laura A.; Bricker, Traci L.; Liang, Chieh-Yu; Joshi, Astha; Bamunuarachchi, Gayan; Seehra, Kuljeet; Schmitz, Aaron J.; Halfmann, Peter J.; Kawoaka, Yoshihiro; Elbashir, Sayda M.; Edwards, Darin K.; Thackray, Larissa B.; Diamond, Michael S.; Boon, Adrianus C. M.
title: mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
date: 2021-12-29
journal: bioRxiv
DOI: 10.1101/2021.12.29.474432
sha: 7f5b26a4c85e632daa1fc7ae1c0fd10eea8761c6
doc_id: 801799
cord_uid: yvapzwm2

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune evasion properties have arisen, which could jeopardize recently deployed vaccine and antibody-based countermeasures. Here, we evaluated in mice and hamsters the efficacy of preclinical non-GMP Moderna mRNA vaccine (mRNA-1273) and the Johnson & Johnson recombinant adenoviral-vectored vaccine (Ad26.COV2.S) against the B.1.621 (Mu) South American variant of SARS-CoV-2, which contains spike mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, and D950N. Immunization of 129S2 and K18-human ACE2 transgenic mice with mRNA-1273 vaccine protected against weight loss, lung infection, and lung pathology after challenge with B.1.621 or WA1/2020 N501Y/D614G SARS-CoV-2 strain. Similarly, immunization of 129S2 mice and Syrian hamsters with a high dose of Ad26.COV2.S reduced lung infection after B.1.621 virus challenge. Thus, immunity induced by mRNA-1273 or Ad26.COV2.S vaccines can protect against the B.1.621 variant of SARS-CoV-2 in multiple animal models.

boosted via intramuscular route with 0.25 or 5 µg of mRNA-1273 or control mRNA vaccine ( Fig  3A) . Serum was collected 21 days after the second immunization, and antibody responses were 178 evaluated by FRNT. As expected, serum from 129S2 mice immunized with the control mRNA 179 vaccine did not neutralize virus infection (Fig 3B) . In contrast, serum from mice immunized with 9 µg dose of mRNA-1273 inhibited infection of WA1/2020 N501Y/D614G and B.1.621 to a lesser viruses (Fig 3B) . Also no significant difference (P > 0.5) was observed in a pairwise comparison of the neutralization titer against WA1/2020 N501Y/D614G and B.1.621 in serum from 129S2 187 mice immunized with high and low dose mRNA-1273 vaccine (Fig S2C) .

We next challenged immunized 129S2 mice with 10 5 PFU of WA1/2020 N501Y/D614G or 189 B.1.621 via an intranasal route. Weights were recorded for 4 days before the animals were 190 sacrificed, and nasal washes and the left lung lobe were collected for viral burden analysis.

Control animals challenged with the WA1/2020 N501Y/D614G virus lost ~10% of their starting 192 body weight by 4 dpi (Fig 3C) . Immunization with 0.25 and 5 µg of mRNA-1273 reduced the 193 weight loss (P < 0.001 and 0.01 respectively, Fig 3C) . Inoculation of control-vaccinated 129S2 194 mice with B.1.621 resulted in ~7% weight loss at 4 dpi (Fig 3D) , and immunization with 0.25 or 195 5 µg of mRNA-1273 prevented this weight loss (P < 0.05).

In animals vaccinated with the control mRNA and challenged with the WA1/2020 197 N501Y/D614G virus, we detected ~10 6 copies/mL of N gene transcript (Fig 3E) in the nasal 198 wash at 4 dpi. Immunization with 0.25 or 5 µg of mRNA-1273 reduced WA1/2020 199 N501Y/D614G viral RNA levels in the nasal wash (~200-fold, P < 0.001). In mice vaccinated 200 with the control mRNA vaccine and challenged with B.1.621, we detected ~10 6 N gene 201 transcript copies per mL in the nasal wash (Fig 3E) . Immunization with 0.25 µg or 5 µg of 202 mRNA-1273 reduced the viral RNA levels substantially (~200-fold, P < 0.001; Fig 3E) . Viral 203 burden also was measured in lung homogenates of these same animals. In the control mRNA 204 group challenged with the WA1/2020 N501Y/D614G virus, we detected ~10 8 copies/mg of N 205 gene transcript (Fig 3F) and > 10 6 PFU/g of infectious virus (Fig 3G) in lung homogenates.

Immunization with 0.25 µg of mRNA-1273 effectively reduced the viral RNA (10 6 -fold, P < 0.001, 207 Fig 3F) and infectious virus levels (1,000-fold, P < 0.001, Fig 3G) , although some animals 10 showed breakthrough infection. Immunization with 5 µg dose of mRNA-1273 also reduced the 209 levels of viral RNA (10 6 -fold, P < 0.001) and infectious virus (1,000-fold, P < 0.001, Fig 3F-G) .

the lung homogenates ~10 7 copies/mg of viral RNA transcript (Fig 3F) and ~10 6 PFU/g of 213 infectious virus (Fig 3E) . Immunization with 0.25 or 5 µg doses of mRNA-1273 significantly 214 reduced B.1.621 viral RNA (10 5 -fold, P < 0.0001) and infectious virus (1,000-fold, P < 0.0001) 215 levels in the lung (Fig 3F-G) to a similar degree after WA1/2020 N501Y/D614G challenge.

The reduction in viral burden in the lungs of mice immunized with 0.25 or 5 µg of mRNA- [19, [21] [22] [23] [24] . Groups of 5-6 week-old male hamsters were 228 immunized once with 10 8 or 10 10 dose of the Ad26.COV2.S vaccine (Fig 4A) . Serum was 229 collected 21 days later, and antibody responses were evaluated by ELISA and FRNT. As 230 expected, serum from control hamsters that received PBS did not bind viral S protein (Fig 4B) .

antibody titer between WA1/2020 and B.1.621 for the high (P < 0.0001) and low (P < 0.001) 241 dose Ad26-COV2.S immunized hamsters (Fig S2D) .

Seventy days after immunization, the hamsters were challenged via an intranasal route with 243 10 3 PFU of WA1/2020 or B.1.621. Four days later, the animals were sacrificed, and a nasal 244 wash and the left lung lobe were collected for viral burden analysis. In the nasal wash of control 245 animals challenged with the WA1/2020 virus, we detected ~10 6 copies of the N gene transcript 246 per mL of nasal wash (Fig 4D) and ~10 4 PFU/mL of infectious virus (Fig 4E) . Immunization with 247 10 8 or 10 10 dose of Ad26.COV2.S did not reduce the viral RNA levels in the nasal wash ( Fig   248   4D ), although the infectious virus titer was decreased by 16 and 46-fold (P > 0.05 and < 0.05 249 respectively, Fig 4E) . Upon challenge of hamsters with B.1.621, we detected ~10 6 N gene 250 copies per mL (Fig 4D) and ~10 3 PFU/mL of infectious virus (Fig 4E) in the nasal wash.

Immunization with 10 8 or 10 10 dose of Ad26.COV.2 reduced the N gene copy number 19-fold (P 252 > 0.05, Fig 4D) . In comparison, the infectious virus titer was reduced by 2 and 17-fold (P > 0.05 253 and < 0.05 for 10 8 and 10 10 dose respectively, Fig 4E) 

We also measured the viral burden in lung homogenates of hamsters. In the control group 255 challenged with WA1/2020, the N gene copy number was ~10 7 copies per mg (Fig 4F) and the 256 infectious virus levels were ~10 7 PFU/mL (Fig 4G) . Immunization with the 10 8 or 10 10 dose of 257 Ad26.COV2.S reduced the viral RNA (11 and 360-fold, P > 0.05 and < 0.01) and infectious virus 258 (66 and 4800-fold, P = 0.06 and < 0.001) levels (Fig 4F-G) . After B.1.621 challenge of the 12 infectious virus in the lung (Fig 4G) . Immunization with the 10 8 or 10 10 dose of Ad26.COV2.S 261 reduced the viral RNA (7 and 540-fold, P > 0.05 and < 0.05) and infectious virus (100 and 262 25,500-fold, P = 0.13 and < 0.001) levels (Fig 4F-G) . 

The antibody response after vaccination varied between the mouse and hamster models.

Immunization of mice with 5 µg of mRNA-1273 or 10 10 Ad26.COV2.S induced serum 295 neutralizing antibody responses with a GMT of > 10,000 in both 129S2 and K18-hACE2 mice. In 296 contrast, in Syrian hamsters, the GMT against WA1/2020 was ~10-fold lower than in mice, yet 297 still several fold higher than that observed in humans vaccinated with one dose of Ad26.COV2.S 298 [27] [28] [29] [30] . The reason for this difference in vaccine response between mice and hamsters 299 remains unknown. It is possible that the hamster immune response targets different epitopes on 300 the spike protein. Alternatively, the spike protein contains fewer T cell epitopes for hamsters 301 compared to the mouse, although that seems unlikely given the size of the antigen. The Syrian 302 hamster also may be a more tolerogenic, perhaps due to its complex microbiome as opposed to 303 the SPF microbiome of 129S2 and K18 TG mice. Mice that received the microbiome from pet 304 stores or from field mice had blunted vaccine responses compared to laboratory-housed mice in 305 pathogen-free facilities [31] . Additional studies are required to elucidate the causes for this 

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-18

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant 27

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized 33 (open symbols)

**** *** **** ****